Cost-effectiveness of the Port Delivery Platform compared with intravitreal injection of anti-vascular endothelial growth factor for patients with neovascular age-related macular degeneration. (PubMed, BMC Ophthalmol) - Oct 16, 2026 - "Compared to aflibercept IVIs under a T&E regimen for bilateral nAMD, universal use of the PDP with 24-week refills is unlikely to be considered cost-effective in Norway. However, the PDP may be considered high-value for patients needing frequent IVI or facing long travel distances."
Clinical • HEOR • Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
|
|
Emily A Burger; Ivar Sønbø Kristiansen; Michelle Mies Elisabeth Siekerman; Ragnheiður Bragadóttir; Øystein Kalsnes Jørstad
|